论文部分内容阅读
采用免疫单向扩散法检测了肺源性心脏病(急性期、缓解期和恶化期)58例,慢性支气管炎20例及风湿性心脏病10例患者血浆纤维粘连蛋白(Fibronectin,FN)含量。60例健康成人作为对照组。分析了血浆FN含量和呼吸衰竭、感染程度及不同类型酸碱紊乱的关系。结果表明:对照组血浆FN含量为322.4±60mg/L,慢性支气管炎组为363±40mg/L,风湿性心脏病组为333.5±48mg/L。肺源性心脏病急性期FN明显降低,平均为146±67mg/L;缓解期逐渐恢复(286±62 mg/L);恶化期则极度降低(101±39mg/L)。重度呼吸衰竭、肺部感染和酸碱失衡者,FN均明显降低。作者认为:血浆FN可作为肺源性心脏病患者估价病情和预后的一项可靠指标。FN减低的原因可能与肺源性心脏病患者急性期和恶化期消耗增加和合成减少有关。
Fifty-eight cases of pulmonary heart disease (acute stage, remission and exacerbation stage), 20 cases of chronic bronchitis and 10 cases of rheumatic heart disease were tested for the level of Fibronectin (FN) in the patients with pulmonary heart disease. Sixty healthy adults served as control group. The relationship between plasma FN levels and respiratory failure, the degree of infection and different types of acid-base disorders was analyzed. The results showed that the content of FN in the control group was 322.4 ± 60mg / L, that of the chronic bronchitis group was 363 ± 40mg / L, and that of the rheumatic heart disease group was 333.5 ± 48mg / L. FN in acute phase of pulmonary heart disease was significantly lower, with an average of 146 ± 67mg / L; the recovery gradually recovered (286 ± 62mg / L) and the deterioration was extremely decreased (101 ± 39mg / L). Severe respiratory failure, pulmonary infection and acid-base imbalance, FN were significantly lower. The authors believe that: plasma FN can be used as a reliable indicator of disease progression and prognosis in patients with pulmonary heart disease. The reason for the decrease of FN may be related to the increased consumption and the decreased synthesis in acute and exacerbation of patients with pulmonary heart disease.